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s u m m a r y 
The degree of surveillance data and control strategies for invasive meningococcal disease (IMD) varies 
across the Asia–Pacific region. IMD cases are often reported throughout the region, but the disease is 
not notifiable in some countries, including Myanmar, Bangladesh and Malaysia. Although there remains a 
paucity of data from many countries, specific nations have introduced additional surveillance measures. 
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p  ntroduction 
The Gram-negative bacterium, Neisseria meningitidis , is a human
ommensal/pathogen that colonizes the nasopharyngeal mucosa. It
an cause invasive meningococcal disease (IMD) by passing into
he bloodstream via the mucosal membrane. 1 Although the pre-
ise mechanisms by which this occurs are not fully understood, 2 it
s well established that the bacterium’s virulence is associated with
he expression of a polysaccharide capsule. 3 Of the 12 polysaccha-
ide capsules, six (A, B, C, W, X, Y) are associated with most IMD
ases, 3 which includes potentially life-threatening conditions, such
s meningitis and/or septicemia. There are approximately 1.2 mil-
ion IMD cases each year worldwide and case fatality rates (CFRs)
ave been documented to range from 4.1% to 20.0%. 4 , 5 
The Global Meningococcal Initiative (GMI) is a multidisciplinary
roup of scientists, clinicians and public health officials that was
ormed to raise awareness of IMD through education and research.
ince the GMI’s inception in 2009, a series of meetings have been
eld to discuss the latest data in surveillance and epidemiology, as
ell as control strategies and immunization schedules across dif-
erent regions. 6 , 7 
As part of the GMI’s activities, a group of experts has conducted
 review of IMD epidemiology and control strategies in the Asia–
acific region, as well as wider issues that may affect the incidence
f IMD, such as occupational risks, religious beliefs and modes of
ransmission. The objectives of this review are to: (i) provide an
pdate on IMD surveillance and prevention in the Asia–Pacific re-
ion; (ii) highlight the potential risk of IMD in high-risk groups,
articularly for those participating in mass gatherings; and (iii) ex-
lore current barriers to vaccination, with a focus on Hajj pilgrims
nd religious beliefs. 
In addition to the above objectives, several other topics that
re not necessarily exclusive to the Asia–Pacific region are covered.
hese include: (i) unusual transmission pathways of meningococci;
ii) the impact of conjugate vaccines and meningococcal serogroup
 (MenB) vaccination on disease and carriage; and (iii) the risk of
nvasive disease in specific occupations. 
he surveillance, epidemiology and prevention of IMD in the 
sia–Pacific region 
urveillance of IMD 
Surveillance is of critical importance in controlling meningococ-
al disease, with the principal drivers of surveillance networks be-
ng outbreak detection; incidence monitoring; disease burden es-
imation; antibiotic resistance analyses; serogroup and strain dis-
ribution assessments; and control strategy evaluations. 8 Although
any countries have the capability to confirm suspected IMDd similar across the represented countries ( < 0.2 cases per 10 0,0 0 0 per-
minant serogroups of Neisseria meningitidis being B, W and Y, although
t in some areas. Resistance to ciprofloxacin is also of concern, with the
resistant clonal complexes (e.g., cc4821) being a priority. Meningococcal
a few National Immunization Programs, but is recommended for high-risk
ch as pilgrims) and people with complement deficiencies or human im-
th polysaccharide and conjugate vaccines form part of recommendations.
ons remain limiting factors in vaccine uptake, despite conjugate vaccines
rriage. 
0 Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY-NC-ND license
( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
ases, the structural complexity of surveillance networks varies
cross regions (be it regionally, nationally or internationally). 7 Such
etworks may utilize passive, active or sentinel surveillance strate-
ies, with cost, resource and national disease burden shaping the
ystem health ministries adopt. A number of countries do not have
n active, laboratory-based surveillance system in place. 4 
In a similar fashion to global trends, surveillance approaches
iffer across the Asia–Pacific region. IMD cases are often reported,
ut IMD is not recognized as a notifiable disease in some coun-
ries, including Myanmar, Bangladesh and Malaysia. In Myanmar,
here is poor IMD awareness among physicians, with meningitis
ases (without a characteristic rash) being under-recognized and
nder-reported. However, the under-estimation of IMD burden is
ot solely attributed to those countries with no established surveil-
ance system. The incidence of bacterial meningitis in children is
ften underestimated in South Korea despite surveillance effort s.
lthough the reasons underlying such a trend are complex, there
re several identifiable factors, including the prevalent use of an-
ibiotics and limited diagnostic tools (generally, South Korean and
epal hospitals only have access to culture method for case con-
rmation). Although not readily available in laboratories across the
egion, polymerase chain reaction (PCR) testing is a critical tool,
hich can help to diagnose suspected meningococcal cases, espe-
ially when culture specimens are negative for N. meningitidis . 
Geographical limitations and regional capabilities also factor
nto the effectiveness of surveillance networks across the Asia–
acific region. Cambodia has a robust surveillance network in
lace, with suspected cases being referred from district centers to
rovincial units, and subsequently to national hospitals. The coun-
ry also has 20 microbiology laboratories, with a range of capa-
ilities. However, these units serve up to 20 0 0 private and pub-
ic hospitals throughout the country, with 10 laboratories located
n the capital, Phnom Penh. Conversely, Australia operates a state-
ased IMD surveillance system, with each state or territory funding
ts own microbiology reference laboratory. All cases are reported
rom the states nationally through the National Notifiable Diseases
urveillance System. 
ncidence of IMD 
IMD incidence is fairly similar across the Asia–Pacific region,
anging from 0.02 to 0.2 cases per 10 0,0 0 0 persons per year in the
hilippines to Singapore, respectively. 9 However, there have been
igher reported incidences in certain countries or within specific
ub-populations. In New Zealand, for instance, the average inci-
ence of IMD was 2.3 per 10 0,0 0 0 persons in 2019, with cases
anging from 0.0 to 4.5 per 10 0,0 0 0 persons, depending on the dis-
rict health board. 10 
Although IMD incidence is low in South Korea 11 ( ∼0.05 cases
er 10 0,0 0 0 persons per year), the number of cases is higher




















































































































a  among army recruits ( ∼2.2 cases per 10 0,0 0 0 persons per year). 12 
Army personnel from differing socioeconomic backgrounds live
in close proximity and undertake operations whereby maintain-
ing good hygiene is challenging. 13 As a result of IMD outbreaks
among this sub-population, the South Korean Government insti-
tuted a meningococcal vaccination program under the 2012 Mili-
tary Healthcare Service Act. 13 
In Australia, higher IMD notification rates are observed within
the Aboriginal and Torres Strait Islander populations in the North-
ern Territory (13 cases per 10 0,0 0 0 persons in 2017). This higher
risk may be attributed to factors associated with socioeconomic
disadvantage and living in over-crowded and remote communities.
The IMD incidence among this demographic has been consistently
higher than that observed in the non-Indigenous population across
Australia, particularly in those aged 0–9 years. 14 
The burden of meningococcal disease is high among children
and adolescents throughout the Asia–Pacific region. In the Philip-
pines, ∼75% of the total number of confirmed IMD cases were
among those aged 0–14 years in 2012–2013. 15 High incidence rates
among infants and children (0–4 years) have also been observed
in Singapore and South Korea, with 1.6 (2018) and ∼1.35 (2010)
cases per 10 0,0 0 0 persons, respectively. IMD incidence is partic-
ularly acute among infants < 1 year in Nepal, as was in evidence
in the 1983 meningococcal meningitis outbreak in the Kathmandu
Valley. 
CFRs are high in some countries across the region. With a
high burden of IMD in young infants and children, the Philippines
reported a CFR in the same demographic of ≥50%. In Thailand,
there was a similar CFR across all age groups at ∼40% in 2012
for meningococcal meningitis cases. Although the overall IMD in-
cidence is low in China ( < 0.1 cases per 10 0,0 0 0 persons per year),
the CFR is > 10% and, similarly, in Japan the CFR was estimated at
∼16% during the period of April 2013 to June 2018. 
Serogroup distribution 
In the countries represented at the recent GMI meeting, the
predominant reported serogroups were B, W and Y. 
Serogroup B is prevalent in many Asia–Pacific countries/regions,
both in IMD cases and carriage. 9 , 16 A large proportion of IMD
cases ( n = 99/113; 88%) in Taiwan from 2005 to 2018 were caused
by serogroup B – a 34% increase over the previous 9-year pe-
riod. With regards to the epidemiological data based on labora-
tory surveillance during 2015–2017 in China, MenB accounted for
35.8% ( n = 53/148) IMD cases. Based on data collected from the Na-
tional Epidemiological Surveillance on Infectious Disease (NESID)
network in Japan, serogroup B accounted for 20% ( n = 13/65) of
reported IMD cases between January 2017 and June 2019. In
Australia, over half of the reported IMD cases were caused by
serogroup B during the first 6 months of 2019 ( n = 46/89; 52%);
although cases due to this serogroup have been declining nation-
ally since 2017. 17 Carriage of serogroup B meningococci is also high
in South Korea, with a carriage rate of 24.5% reported among 1460
first grade high school students (aged 16–17) in 2015. 18 
Serogroup W circulation is significant across the Asia–Pacific
region. Based on PCR testing, the Philippines reported that 16.7%
( n = 8/48) of blood and cerebrospinal fluid (CSF) specimens col-
lected in 2018 were serogroup W. A higher percentage was re-
ported in Australia during the first six months of 2019, with
25 out of 89 IMD cases (28%) being attributed to serogroup W
(48% of these cases resulted in intensive care unit (ICU) admis-
sions). 17 There was a similar proportion of serogroup W cases
among laboratory-confirmed IMD in New Zealand during the same
period (30%; n = 30/99). 19 
Antibiotic-resistant serogroup C (MenC) and MenB strains con-
tinue to emerge in parts of Asia. Prior to 2003, a small fractionf IMD cases were associated with MenC in China. However, there
ere a number of MenC outbreaks caused by clonal complex (cc)
821 between 2003 and 2005 in Anhui province. 20 cc4821 has
ince spread to all provinces across the country, accounting for
 95% of MenC cases. In addition, this particular clonal complex in
enB and MenC cases is non-susceptible to ciprofloxacin, leading
o warnings that this antibiotic should be prescribed with caution
s a prophylactic treatment. 21–23 
revention and control strategies 
There are a range of prevention and control strategies employed
cross the Asia-Pacific region; however, most countries do not in-
lude meningococcal vaccination as part of their National Immu-
ization Programs (NIPs). Although practices vary, chemoprophy-
axis is commonly prescribed, with immunization only being rec-
mmended for those in high-risk groups. 24 These groups may in-
lude people with complement deficiencies, human immunodefi-
iency virus (HIV), or those attending a pilgrimage or a mass gath-
ring in another country/region. Such recommendations are pro-
oted in Vietnam, the Philippines, New Zealand, Thailand, Taiwan,
ingapore and Indonesia. With sporadic cases and limited out-
reaks in small communities, there is no direct impetus to incor-
orate meningococcal vaccination into the NIP in these countries.
accinations may still be accessible through private clinics, but
ost is a limiting factor in vaccine uptake. For instance, a meningo-
occal vaccine is available in Myanmar, but can cost up to $70 USD
er dose. 
Other countries in the region have incorporated different
eningococcal vaccines into their NIP in response to outbreaks
r the emergence of virulent strains. Owing to the increased in-
idence of IMD related to serogroup B in South Australia, the state
as now introduced the four-component MenB (4CMenB) vaccine
nto the immunization program. 25 The meningococcal serogroups
, C, W and Y (MenACWY) conjugate vaccine is also funded under
he NIP in Australia. 26 China has a multistage meningococcal vacci-
ation program with children between 6 and 18 months receiving
wo doses of a meningococcal serogroup A (MenA) polysaccharide
accine (3 month interval), with subsequent doses of meningo-
occal serogroup A and C (MenAC) polysaccharide vaccine (free of
harge) or MenAC conjugate vaccine (at parents’ own cost) at 3 and
 years. 27 
Chemoprophylaxis is in common usage despite the lack of na-
ional recommendations in some areas. The Chinese Center for Dis-
ase Control has no strict protocols for prophylactic treatments,
hich has led to each province prescribing different antibiotics
ased on local guidance. In Vietnam, all close contacts of a sus-
ected IMD case will receive either ciprofloxacin or azithromycin. 
eningococcal immunization and treatment strategies 
olysaccharide and polysaccharide conjugate vaccines 
As discussed previously, the polysaccharide capsule is the
eningococcus’ primary virulence factor. 3 , 28 The underlying chem-
stry of the repeating saccharide units defines the capsular group. 28 
Unconjugated polysaccharide vaccines cross-link B-cell recep-
ors to drive cell differentiation to plasma cells. However, the
ody’s immune system does not effectively recognize repeating
accharide units and so this differentiation only stimulates im-
unoglobulin G2 (IgG2) and M (IgM) production, but does not
nduce memory B-cells. 28 , 29 Therefore, polysaccharide vaccines do
ot stimulate immunological memory and repeated vaccinations
ay actually result in hyporesponsiveness. 29 , 30 
To overcome these limitations, the polysaccharide is linked to
n immunogenic carrier protein, such as tetanus or diphtheria tox-




























































































































H  id. The resulting polysaccharide conjugate vaccine is internalized
nd processed within a B cell. Peptide-specific T cells subsequently
upport cell maturation and the production of immunoglobulin
1 and G3, with the process also inducing a B-cell memory re-
ponse. 28 As this adaptive immune response is not predicated on
-cell maturation, conjugate vaccines are immunogenic in infants
as well as older children and adults). 31 , 32 
As well as protecting against disease, polysaccharide conjugate
accines may also prevent the acquisition of meningococcal car-
iage; 33 although there have been few clinical studies that have
ssessed this effect. 34–36 Most trials have been conducted in con-
unction with mass vaccination campaigns. 37–39 Despite this, trials
onducted in Africa have offered key insights into meningococcal
arriage reduction following vaccination. A recent study was de-
igned to assess the effect of MenAfriVac (PsA-TT) (meningococcal
erogroup A [MenA] conjugate vaccine) on meningococcal carriage
n Burkina Faso following a vaccination campaign. 39 Two years af-
er the campaign, there remained a significant reduction in MenA
arriage, with MenA carriage prevalence at 0.02%; a decrease from
.39% (pre-vaccination). 39 Further surveillance data from 18 coun-
ries in sub-Saharan Africa indicates a 99% decline in MenA disease
ollowing the introduction of PsA-TT. 
Meningococcal serogroup B vaccines 
There remain a number of outstanding issues with respect to
enB vaccine development with early effort s to develop a capsular
olysaccharide-based formulation failing to produce an immuno-
enic response. 40–42 The lack of immunogenicity is attributable to
he MenB capsular polysaccharide being a mimic of human neural
ell adhesion molecules. 43 
Outer membrane vesicles (OMVs) derived from meningococci
ave also been used to develop MenB vaccines. Such OMVs
ontain the surface-exposed protein, PorA, which can induce
erum bactericidal antibodies; however, PorA is highly antigeni-
ally variable. 44 , 45 This results in OMV-based vaccines being strain-
pecific and unable to generate antibodies against heterologous
trains. 46 
To mitigate this limitation, efforts have subsequently focused
n developing MenB vaccines with multiple antigens to maximize
train coverage. Three of the main antigens in the multicompo-
ent 4CMenB vaccine were identified using reverse vaccinology.
he subsequent final formulation consisted of Factor H binding
rotein (fHbp), Neisseria Adhesin A (NadA) and Neisserial Hep-
rin Binding Antigen (NHBA). These outer membrane proteins were
hen added to OMV [containing PorA P1.4] from the New Zealand
accine strain (NZ 98/254) to further enhance strain coverage. 46 , 47 
ince the coverage of protein-based vaccines is dependent on suf-
cient (i) antigenic similarity and (ii) surface expression of cor-
esponding peptide within target strains, a system for estimating
train coverage, the Meningococcal Antigen Typing System (MATS),
as been developed. 47 , 48 There is also a second licensed MenB vac-
ine (Trumenba R ©, MenB:fHbp [Pfizer]), which contains recombi-
ant fHbp from each of the two subfamilies A and B found in N.
eningitidis . 49 
Estimates since its introduction in England suggest 4CMenB
in a 2 + 1 schedule) has a vaccine effectiveness in infants (VE)
f 59.1% against vaccine-preventable strains. 49 The same study in
ngland has shown that the vaccine has led to a 75% reduction in
he incidence of MenB in infants eligible for vaccination. 50 There is
imited evidence to suggest the 4CMenB vaccine may disrupt car-
iage acquisition in adolescents. 51 , 52 
It should be recognized that the prevalence of MenB is high
cross various countries in the Asia–Pacific region (as indicated in
able 1 ), with limited MenB vaccination programs, excluding Aus-
ralia. However, some countries, such as China, have now started
o work on developing a suitable MenB vaccine. ntibiotic resistance 
Antimicrobial resistance was a recurring theme during this
ear’s GMI roundtable meeting. Probabilistic treatment for sus-
ected N. meningitidis cases relies on the effective use of antibi-
tics, with beta-lactam agents often being prescribed. It is well
ocumented, however, that invasive N. meningitidis species are be-
oming more resistant to such treatments. 53 Resistance to this spe-
ific class of antibiotics is rarely due to beta-lactamase producing
eningococci. 54 More frequently in N. meningitides , mutations in
enicillin-binding proteins within bacterial species may also limit
he effectiveness of penicillin and are the leading cause of re-
uced susceptibility among meningoccoci. 55 Although extremely 
are among meningococci, beta-lactamase is an ongoing source
f concern, with recent WGS analysis identifying the presence
f a ROB-1-type beta-lactamase gene more typically found in
aemophilus influenzae . 53 , 55 
In Australia, an annual report monitoring the antimicrobial sus-
eptibility of IMD isolates ( n = 210), indicated that 1.4% ( n = 3/210)
ere resistant to penicillin (minimum inhibitory concentration
MIC] ≥1 mg/L) with a decreased susceptibility (MIC 0.06–0.5 mg/L)
o penicillin observed in 93.8% ( n = 197/210). The three penicillin-
esistant isolates were all from Queensland, with 2 being attributed
o MenW and 1 to MenC. 56 Penicillin-resistant N. meningitidis iso-
ates have also been detected in Thailand and Bangladesh; albeit
o a lesser degree than those found in Australia (Thailand: isolates
ere resistant to penicillin with a MIC ≥0.125 μg/mL). 57 
Antimicrobial resistance across the Asia-Pacific region is not ex-
lusive to beta-lactam antibiotics. A ciprofloxacin-resistant strain of
enC (cc4821) that emerged in China 20 has now been identified
n both Canada and Japan. 58 , 59 Resistance to fluoroquinolones has
een linked to mutations in the gyrA and parC genes in N. menin-
itidis isolates. 60 Owing to the spread of this clonal complex, there
s the potential for the strain to reach sub-Saharan Africa. This,
n turn, may pose issues in the Kingdom of Saudi Arabia where
iprofloxacin is used as a prophylactic treatment for people making
he pilgrimage from the meningitis belt to Makkah (Mecca) during
he Hajj. 61 
equence analysis and whole genome sequence surveillance across 
he Asia–Pacific region 
Sequence analysis is applicable for many targets and offers
ighly transportable data. Whole genome sequence (WGS) analysis
s being utilized in several countries within the Asia-Pacific region
o analyze outbreaks, population structures, and the emergence of
ew strains. 
ustralia 
Under current practice in Queensland, Australia, pathology lab-
ratories will test specimens for N. meningitidis by either culture
r PCR samples. Positive specimens or isolates are then sent to
he Queensland Public Health Microbiology laboratory, as the state
eisseria reference laboratory, for further testing. 62 The laboratory
as extensive experience in WGS and national accreditation for
igh-throughput sequencing, which can process a large number of
NA sequences in parallel (known as massively parallel sequenc-
ng). Similar testing workflows occur in the other states and terri-
ories of Australia, with varying levels of WGS in use. Surveillance
n Australia for N. meningitidis is coordinated nationally through
he National Neisseria Network (NNN), which includes molecular
enotyping generated in silico from genomic data for several states
WGS for surveillance of N. meningitidis at the Queensland Public
ealth Microbiology laboratory has assisted in better understand-
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Philippines Y • 0.02–0.1 cases/100,000 persons/year, with ∼100 
cases/year and no seasonal variation 
• CFR is highest among infants and young children 
∼≥50% 
• Between Jan–Jun 2019, there were 130 IMD cases 
and 68 deaths, according to the Department of 
Health 
• Serogroup B was the most prevalent in blood and 
CSF PCR surveillance testing (68% of cases) 
(2017–2018) 
• Vaccines are available, but only privately, and not 
included in the NIP 
• The MenACYW-135 vaccine is only recommended 
for children > 9 months old at high risk of IMD 
(e.g., HIV positive; persistent complement 
deficiencies; travelers moving to an epidemic 
region) 
China Y 
• Overall incidence of IMD is low ( < 0.1 
cases/100,000 persons/year) 
• CFR is considered high at > 10% 
• Since 2005, serogroup B (cc4821) cases have been 
increasing, as well as W (cc11). Serogroup Y cases 
(cc23; cc175) have also increased 
• A ciprofloxacin-resistant clonal complex within 
serogroup C (cc4821) has also emerged and 
spread across at least 18 countries 
• Both MenA and MenAC polysaccharide/conjugate 
vaccines are incorporated into the NIP for 
children 
• Children (6–18 months): Two doses of MenA. 
Subsequent MenAC dose at 3–6 years 
• The MenACYW polysaccharide vaccine is 
available, but will need to be paid for by the 
parents 
Japan Y 
• 0.028 cases/100,000 persons/year (2014) 139 
• Average CFR ∼15% (April 2013–June 2018) 140 
• Serogroups Y, C and B are the predominant 
bacterial variants, with serogroup Y accounting 
for ∼45% of reported IMD cases 142 
• There are low rates of carriage across Japan 
(0.4–0.8% of the population) 
• The MenACWY conjugate vaccine is licensed, but 
not included in the NIP 
Australia Y 
• 1.1 cases/100,000 persons (2018) 141 
• 281 IMD cases in 2018, with 16 deaths 
reported 141 
• CFR was 6% in 2018, compared with 10% in 
2,017, 142 
• Serogroups B, W and Y are the predominant 
serogroups across Australia 142 
• MenB remains prevalent among adolescents 
(15–19 years) and infants 142 
• MenACWY conjugate vaccine is funded for 1 year 
olds and14–19 year olds under the NIP 
• There is a state government funded 4CMenB 
vaccination schedule in South Australia 
• The 4CMenB vaccine will soon be included in the 
NIP for Aboriginal and Torres Strait Islander 
children up to 2 years of age 
New Zealand Y 
• Notification rate was 2.3/100,000 persons in 
2,019, 143 
• MenB, W and Y are the predominant 
serogroups 143 
• Most cases are among those < 1 year 143 
• CFRs were 7.9%, 12.8% and 8.3% for serogroups B, 
W and C, respectively, between 2014 and 
2,019, 143 
• No meningococcal vaccines included in the NIP 
• MenC and MenACWY conjugate vaccines are 
recommended for certain high-risk groups (e.g., 
HIV positive, complement deficiencies) 




• 9 clinically suspected meningitis cases linked to 
meningococci (2.3% of CSF samples) between 
2017 and 2018 144 
• All N. meningitidis isolates belonged to serogroup 
A 144 
• Between 1982 and 1984, there was a 3-fold 
increase in meningococcal meningitis cases in 
Kathmandu. This declined after the introduction 
of a mass vaccination campaign 145 
• Vaccination is not included in NIP 
• Vaccination with bivalent ( A + C ) or quadrivalent 
(A, C, Y and W) meningococcal vaccine is 
recommended for people at risk 
Myanmar N 
• There have been five IMD outbreaks since 1990 
• IMD occurs sporadically throughout Myanmar, 
with 34 deaths in a total of 391 cases since 2000 
• Both serogroups A and B were detected in recent 
outbreaks 
• Vaccination not included in NIP 
• MenACWY conjugate vaccine is commercially 
available, but expensive ( ∼$70 per dose) 
South Korea Y 
• 0.05 IMD cases/100,000 persons in 2014. 146 
Estimated annual incidence is 2.2 cases/100,000 
persons in the Korean Army 13 
• Highest incidence among young infants (0–4 
years) 
• Serogroup B and C are the most common 
meningococcal carriage isolates among Korean 
adolescents; although serogroup distributions are 
consistently changing 18 
• IMD remains an under-recognized disease in 
South Korea based on the limitations of culture 
surveillance methods 
• There is a mandatory vaccination program in 
place for Korean Army recruits, which includes a 
meningococcal vaccine 
( Continued on next page ) 
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Malaysia N • There is limited data in Malaysia on MD 
epidemiology 
• In Sarawak, a Malaysian state, there was a peak 
in the number of meningococcemia cases ( n = 7). 
In 2018, there were four meningococcemia cases 
• Meningococcal vaccination is not routinely 
recommended and there is no formal record on 
vaccination in private clinics 
• Since 1988, Malaysian Hajj pilgrims have received 
a bivalent MenAC vaccine 
Bhutan N • There is limited surveillance data on IMD in 
Bhutan 
• Outbreaks of meningococcemia occurred in 1985, 
2012 and 2016, with two positive blood culture 
cases in 2018 and 2019 
Meningococcal vaccines are not included in the NIP 
Thailand Y 
• Incidence was 0.04 cases/100,000 persons in 
2019. Incidences are generally higher in young 
infants (0–4 years) 147 
• Serogroup B was the most common serogroup 
among cases (1994–1999: 56.3%) 147 
• CFR peaked at 37.5% in 2012 for meningococcal 
meningitis (2006–2015 data) 147 
• Meningococcal vaccination not recommended 
within NIP, but is recommended for those 
attending a mass gathering or those with a 
complement deficiency 
Taiwan Y 
• IMD incidence: 0.008–0.192 cases/100,000 
persons (1993–2019) 148 
• Between 2004–2018, serogroup B was the most 
common N. meningitidis serogroup (88% of cases; 
99/113) 
• Both the cc32 and cc4821 clonal complexes were 
most common among isolates, 149 with B:cc32 
being linked to a IMD outbreak in a high school 
and B:cc4821 at a military camp 
• No routine vaccination 
• Only recommended in contracted hospitals or 
clinics for high-risk groups (pilgrims; those in 
high-risk areas) 
Cambodia N 
• No official data on meningococcal infection in 
Cambodia 
• There have been two cases in Calmette Hospital 
(culture-confirmed) 
• 8 culture-confirmed cases in 2012 at one 
non-governmental organization (NGO) hospital 
• Meningococcal vaccination not included in the 
NIP 
• However, a MenACWY conjugate vaccine is used 
at the IPC’s vaccination center 
Vietnam Y 
• Following an outbreak of IMD (serogroup C) from 
1977 to 1979, there have been sporadic serogroup 
C cases in Ho Chi Minh City (2006 and 2012) 
• Since 2012, serogroup B has been detected in 
IMD cases 
• A carriage study among military personnel in 
2015 indicated carriage rates of between 30% and 
40% (serogroups B and C) 
• A meningococcal vaccine is not included in the 
Expanded Programme on Immunisation 
• Only small communities in cities may be 
recommended for vaccination 
Singapore Y 
• Incidence is ∼0.2 cases/per 100,000 persons/year, 
with 1.6 cases/100,000 persons in young infants 
(0–4 years) 150 
• Since 2004, serogroup B has been the 
predominant serogroup among IMD cases 150 
• There is no formal control strategy in place due 
to the country’s low incidence of IMD 
• MenACYW is recommended in the national 
guidelines for travelers, pilgrims, 
immunocompromised patients, overseas students 
and close contacts 
• MenB vaccination is to be included in the 2020 
guidelines 
Bangladesh Y (small-scale and 
only among the 
pediatric 
population) 
• Limited and sporadic data on IMD incidence in 
Bangladesh ( ∼1 case/100,000 persons [based on 
one meta-analysis]) 
• There was a potential outbreak in 2003–2004 
(serogroup A) 
• 349 cases of sepsis and meningitis over the past 
25 years, which have been attributed to N. 
meningitidis 
• Majority of cases occur in children < 1 year 
• Serogroup B is the most prevalent serogroup in 
IMD, with a median age of 5 months. Between 
1994 and 2009, serogroup A was the most 
prevalent (median age: 36 months) 
• Many clonal complexes of serogroup B are in 
circulation in Bangladesh, with several sequence 
types being specific to the country 
• Two MenB vaccines are available in Bangladesh, 
but coverage is low ( ∼25% of the population) 
( Continued on next page ) 
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Indonesia N • 1995–1996: N. meningitidis cause of meningitis in 
16.7% of bacterially-confirmed cases in children 
< 5 years 151 
• 1998–2002: N. meningitidis detected in 17.6% of 
culture-positive meningitis cases in children < 2 
years 152 
• Outbreak of 14 cases of meningococcal meningitis 
with 6 deaths in 2000 (lab-confirmed N. 
meningitidis serogroup B in one case) 
• MenACWY conjugate vaccine no longer available 
due to religious concerns 
• MenB vaccines are also not available 
• No children < 2 years receive a meningococcal 
vaccination 
• All Hajj and Umrah pilgrims, as well as migrant 
workers and students going abroad, should be 
vaccinated 
India Y 
• 10 cases of N. meningitidis from invasive bacterial 
disease isolates at the Christian Medical College 
in Vellore, between 2014 and 2019 
• No information available on vaccination strategy 
CFR, case fatality rate; CSF, cerebrospinal fluid; IMD, invasive meningococcal disease; NIP, National Immunization Program; MenAC, meningoccoal serogroups A and 












































































q  ing of IMD, including an unusual serogroup found to have caused
a number of IMD cases in Queensland (serogroup E) (E:P1.21–
7,16:F5–36:ST-1157 [cc1157]). 63 Genomics also assisted in charac-
terizing isolates from a cluster of N. meningitidis (predominantly
serogroup C) cases in Queensland, where the single serogroup Y
case within this cluster was confirmed as not being the product of
a capsular switch via MLST. 64 
IMD isolates or sequences from 2017 to 2018 were provided by
all NNN laboratories across Australia to the Microbiological Diag-
nostic Unit (Doherty Institute, University of Melbourne). A coor-
dinated genomics analysis was performed, producing national re-
ports important for understanding the changing epidemiology of
IMD in Australia, particularly the emergence of MenW. 
China 
Prior to the introduction of the MenA polysaccharide vaccine
in the 1980 ′ s, MenA was the most predominant serogroup caus-
ing IMD in China between the 1950s and 1980s, with sequence
types including ST-3, ST-5 and ST-7. 26 Recent genotypic analyses
have elucidated a capsular switch in an ST-7 lineage from MenA to
serogroup X (MenX). 65 , 66 Between the donor and recipient strains,
eight potential recombination sites were identified, indicating the
capsular switch occurred through a recombination involving 8540
base pairs spanning from the ctrC to the galE genes. 65 It has also
been shown this switch can occur at high frequency (6.3 × 10 −6 
per bacterium per μg of DNA). 66 
A MenC cc4821 hyperinvasive strain has increasingly been iso-
lated since 2003 67 and cc4821 has also been identified among
MenB isolates. Capsular switching between the two serogroups is
well documented. 68 A recent study on the lineage of serogroup B
(cc4821) indicates the hyperinvasive MenC strain is the likely ori-
gin, with a characterization of the outer membrane protein genes
showing the two serogroups have similar genotypic profiles. 67 
A recent collaboration between China and the UK has probed
the genetic relationship of cc4821 isolates across 11 countries us-
ing the PubMLST database. The underlying population structure
shows that cc4821 isolates from countries outside of China are
more closely clustered, with the Chinese isolates being more ge-
netically diverse. 
A phylogenetic analysis of serogroup W ST-11 complex
[MenW:cc11] isolates from China indicated that two Chinese sub-
clusters are closely related to, but distinct from, the MenW:cc11
Hajj-strain and South American strain sublineages currently
causing IMD elsewhere around the world (as indicated in
Fig. 1 ). 69 he global spread of cc11 
An update on the global spread of cc11 was provided during the
MI meeting highlighting (i) the presence of the MenW:cc11 Hajj
train sublineage in Russia and Bangladesh, (ii) the MenW:cc11
outh American strain sublineage in Russia, Japan and New
ealand, (iii) the MenW:cc11 Chinese strain sublineage in China
nd Japan, and (iv) a further distinct MenW:cc11 strain in
angladesh. 
The expansion of a penicillin resistant sublineage of the original
K strain of the MenW:cc11 South American strain sublineage that
as first identified in Australia was demonstrated to include coun-
ries in Europe, North America, and the Asia-Pacific region includ-
ng Japan and New Zealand. Additionally, a ciprofloxacin-resistant
train of MenW:cc11 has been identified in China. 
apping out a course to defeat meningitis and raise awareness 
efeating meningitis by 2030: a global roadmap 
There are an estimated 30 0,0 0 0 deaths per year due to bacterial
eningitis across all age groups. 70 Disease is also resulting in a
umber of sequelae, including neurological complications. 71 
In 2017, a global meeting, which involved governments, public
ealth experts and health organizations, convened to outline a vi-
ion to ‘defeat meningitis by 2030 ′ . 72 The overarching goals are to:
i) Eliminate bacterial meningitis epidemics; (ii) Reduce cases and
eaths from vaccine-preventable bacterial meningitis; (iii) Reduce
he risk of disability and improve quality of life. 
A global roadmap has been outlined to achieve this vision. 73 
hree types of phased activities form the roadmap: (i) Set up a
echnical taskforce designed to develop the roadmap; (ii) Conduct
 baseline situation analysis to identify critical gaps and research
dvances; (iii) Conduct an iterative consultation process to estab-
ish consensus through technical and public consultations. As part
f the baseline analysis, several gaps have been identified, which
nclude a sub-optimal use of vaccines globally; a lack of vaccine
ccess; and an inability to control N. meningitidis epidemics partly
s a result of insufficient laboratory capacity. 
The next steps as part of the global roadmap are to develop a
usiness case, identify research priorities and enter into regional
ngagement. 
dvocacy and vaccine hesitancy considerations for the Asia–Pacific 
egion 
In 2017, the Philippines withdrew a dengue vaccine due to
uestions over its safety. 74 Concerns surrounding the vaccine then
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p  pread more widely and without basis to vaccine safety in general,
ueled by a combination of genuine concern and misinformation.
his ultimately led to lower measles vaccine uptake, which was not
he original vaccine under question. 
This case highlights the complex nature of the rising impact of
accine hesitancy that has led WHO to identify it as one of the
op 10 threats to global public health. The concept involves an in-
erconnected set of issues including concerns about adverse events
nd safety; misinformation spread either intentionally or uninten-
ionally; vaccine access; as well as cultural, religious, and sociode-
ographic perceptions and attitudes. 75 Assuming vaccine hesi-
ancy is only synonymous with intentional misinformation spread-
ng alone is therefore inaccurate, even though this factor is impor-
ant. 
All genuine barriers to uptake of vaccines, including hesitancy,
eed addressing if vaccines are to reach all those that need them
nd advocacy has a critical role to play across all aspects. The
onfederation of Meningitis Organisations (CoMO) has developed
he ‘change equation’ to identify the key elements that support
uccessful vaccine advocacy that influences national policy. 76 The
odel identifies three factors; compelling patient stories; health
rofessionals and spokespeople who communicate well; and the
ffective use of compelling evidence and data as key to success.
uch advocacy models can be applied at international, regional and
ational levels, and can be adapted to the intended audience. 
nusual transmission of meningococci 
ransmission through saliva 
It is well established that N. meningitidis is transmitted from
erson to person via air-borne droplets or through contact with
espiratory secretions, 77 with various risk factors being associated
ith carriage and disease (e.g., attending pubs or clubs, intimate
issing and cigarette smoking). 78 However, other studies have in-
icated that sharing drinks or food items with others, leading tohe potential transfer of saliva, may increase the risk of epidemic
eningococcal disease. 79 Despite this, prophylaxis guidelines for
hose who have shared drinks with a confirmed IMD case vary
lobally. 
Meningococcal transmission through saliva has previously been
eported. In these cases, two patients were diagnosed with pri-
ary meningococcal conjunctivitis following incidents in which a
erson had spat directly into their eye. 80 , 81 In the more recent
ase, the patient cultured a MenC isolate. 82 Both patients were
iven chemoprophylaxis, which is in line with the current recom-
endations for primary meningococcal conjunctivitis treatment. 82 
owever, as meningococcal carriage in pure saliva has previously
een documented to be extremely low (0.4%), 81 transmission in
hese cases may have been via oropharyngeal secretions contained
ithin the spit. 
Despite ongoing debate about the source of infection in these
ases, previous studies have found N. meningitidis within saliva.
 study on the salivary flora of 50 school children (7–12 years)
n Scotland showed that N. meningitidis was present in 2 salivary
amples, with a mean surface viable count of colony-forming units
etween 1 × 10 5 and 5 × 10 5 counts per mL. 83 For comparison,
neumococci was found in saliva at the order of 9 × 10 4 counts per
L. 
Detecting bacterial species is dependent upon the sampling
ethod utilized, as well as the site swabbed. A recent study
sed swab sampling to collect saliva, tonsil and nasopharynx sam-
les from 258 students in England. There was a high prevalence
f meningococci ( n = 83;32.2%) among the nasopharynx samples
ompared with low detection in the saliva swabs ( n = 1;0.4%), sug-
esting that low levels of salivary contact are unlikely to transmit
eningococci. 84 In the B Part of It study, saliva drool samples and
ropharyngeal swabs were taken from 239 university students in
ustralia. Based on these data, there was a slightly higher propor-
ion of carriage detected in the oropharyngeal swabs ( n = 16;6.2%)
ompared with the saliva samples ( n = 13;5.4%). 85 Tzeng et al. re-
orted survival of N. meningitidis A, B and C strains is for up to














































































































3 days dried on glass, plastic or metal and concluded that encap-
sulation did not confer greater survival. This suggests that salivary
transfer through bottle sharing and eating should be considered. 
Ano-genitourinary transmission 
The meningococcus and the gonococcus, the two pathogenic
Neisseria , 86 are part of the same genus, but have clinically distinct
characteristics. Meningococci mainly infect the oro/nasopharynx,
with gonococci mainly infecting the ano-genitourinary tract. There
have, however, been numerous reports of diverse meningococci
sampled from ano-genitourinary sites. 87 , 88 In the past decade or
so, invasive outbreaks among men who have sex with men (MSM)
in Europe and North America have been caused by a particu-
lar cc11 lineage 11.2 strain expressing PorA P1.5–1,10–8. In high-
resolution genomic analyses, the isolates responsible for different
outbreaks were interspersed with IMD cases from the wider com-
munity. Co-clustering of MSM IMD outbreak isolates with urethri-
tis and proctitis isolates at a local level, however, suggest a possi-
ble sexual transmission component to the MSM outbreaks. In ad-
dition, the corresponding isolates exhibited distinct adaptations to
the ano-urogenital niche, including the ability to grow anaerobi-
cally and in the case of the urethritis/proctitis isolates, the loss of
a functional fhbp gene. 89 , 90 
Around 2015, in the USA, the emergence of a closely related
sub-strain (US_NmUC) has caused a large multi-state outbreak of
urethritis, predominantly among heterosexual males who have re-
cently participated in oral sex. 91 , 92 The strain responsible also ex-
hibits gonococcus-like adaptations to the ano-urogential site, in-
cluding the loss of the polysaccharide capsule and the ability to
grow anaerobically having acquired a gonococcal nitrite reductase
allele. 93 
The broad lineage 11.2 PorA P1.5–1,10–8 strain remains of par-
ticular concern owing to the ongoing occurrence of invasive dis-
ease outbreaks among MSM, its potential to cause invasive disease
in immunocompromised individuals, its potential for the acquisi-
tion of antibiotic resistance from gonococci, and a general propen-
sity to escape capsular and subcapsular vaccines. The recent arrival
of the US_NmUC strain in the UK in 2019 was reported. 
Mass gatherings and the potential transmission of 
meningococcal disease 
Mass gatherings are an integral part of society, with festivals,
sporting events and religious meetings taking place globally every
year. The congregation of large groups of people into a confined
area carries both logistical implications and public health risks,
particularly with the potential transmission of invasive diseases,
including IMD. 
The Kumbh Mela 
The Kumbh Mela is a major Hindu festival that is celebrated ev-
ery 12 years at sites along the Ganges, the Shipra and the Godavari
rivers in India, with vast tent cities built along the riverbanks. Al-
though a large-scale gathering, the Kumbh Mela is regarded as
a domestic festival that attracts up to 80 million travelling pil-
grims. 94 There have not been any recorded outbreaks of IMD at
the festival, but there have been several meningococcal serogroup
A outbreaks in northern India. 95 Crowded conditions at the Kumbh
Mela may be conducive to IMD transmission. In addition, some pil-
grims may not be immunized, based on previous evidence that 56%
of children in India (1–2 years) are not immunized or are only par-
tially immunized. 96 he Russ celebration 
The Russ celebration (Norwegian: “Russefeiring”) is an annual
vent where graduating high school students celebrate the end of
heir school year in the spring semester. The event involves party-
ng and the consumption of alcohol. In Norway, IMD incidence is
enerally considered low, with serogroups Y, B, W and C (reflect-
ng order of prevalence) in circulation. However, in 2010 there was
 peak in IMD incidence (specifically, serogroups B, C, Y and W)
mong Norwegian adolescents (16–19 years), with an incidence of
 cases/10 0,0 0 0 persons. 
Attendance at the Russ celebration is one risk factor associated
ith meningococcal carriage among Norwegian adolescents (odds
atio [OR]: 2.85; 95% CI: 1.62, 5.02). Other risk factors include shar-
ng bottles (OR: 1.39; 95% CI: 0.69, 2.79), kissing (OR: 2.73; 95% CI:
.58, 4.70), partying (OR: 3.50; 95% CI: 1.45, 8.48), and the con-
umption of smokeless tobacco (OR: 1.56; 95% CI: 1.07, 2.27) – a
actor that is perhaps unique in Scandinavia. 97 
In Norway, there are now meningococcal vaccination recom-
endations in place for teenagers (16–19 years) involved in high-
isk activities, including the Russ celebration. However, there re-
ains debate as to whether this vaccination should be included in
he NIP. 
unerals 
Certain funerals, such as those of political or religious leaders,
ay result in mass gatherings that can pose a potential risk for
MD transmission; although, there is a low number of reported
ases in the literature. 
A number of suspected cases and deaths were reported fol-
owing the funeral of a religious leader in Sinoe County (Liberia),
eld on April 21–22, 2017. The subsequent day, a girl (11 years
f age) experienced vomiting, diarrhea and mental confusion. Over
he next two weeks, there were another 31 reported cases, with 13
eaths. All cases were linked to the funeral, with the US Center for
isease Control (CDC) using PCR to confirm 13 cases as meningo-
occal serogroup C. 98 In six out of 10 specimens subsequently an-
lyzed via metagenomics, there was the presence of a strain with
1–98% similarity to ST-10,217, which previously caused meningo-
occal disease outbreaks in Niger and Nigeria. 99 
he World Scout Jamboree (Japan, 2015) 
In 2015, there were six confirmed IMD cases following the 23rd
orld Scout Jamboree (WSJ) held in the Yamaguchi prefecture,
apan. 100 During the event, there were 33,628 scouts (14–17 years)
n attendance from 155 countries. Three Scottish scouts and one
arent, along with two Swedish scouts contracted IMD; all cases
ere reported to public health agencies following the event. All six
ases were attributed to the same serogroup W strain (ST-11). 100 
enomic analysis indicated that this strain was identical to a strain
hat had recently emerged in the UK; as a consequence, it is likely
his ST-11 strain was introduced from abroad to the WSJ. 101 
There was also a potential transmission of MenW during an in-
ernational flight following the WSJ. In October 2015, an IMD case
nd a carrier were reported in Osaka City (a married couple that
ere on the same return flight as the Scottish scouts). 102 ST-11 was
etected in synovial fluid of the wife, who reported a fever, as well
s arthritis in her right knee (later diagnosed as thrombocytope-
ia). 
This particular outbreak demonstrates how such events can oc-
ur even in countries with a historically low incidence of IMD. It
s important that organizations have a working understanding of
MD incidence in other countries who may be participating in a
ass gathering. 
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Table 2 
Rates of carriage among pilgrims before and after the Hajj, as well as close household contacts (post-Hajj), taken from several studies. 104 
Population Year Overall (%) Pilgrims Pre-Hajj (%) Pilgrims Post-Hajj (%) Pilgrims Household contacts Antibiotic use (%) 
USA 1987 – – 11.6 – 15 
Singapore 2001 8 0.5 17 8.2 41 
8 countries 2001 9.2 8 10.4 – –
USA 2001 1.9 0.9 2.6 – 15–44.8 
Thailand 2001 – – 0 – –
Singapore 2001 – – 16.4 11.1 Some 
Singapore 2002 1.7 2.6 1.3 – 53 
UK 2002 7.5 8.3 6.3 12.9 21 
29 countries 2003 3.2 12.8 
Iran 2003 4.9 5.2 4.6 – > 58.2 
14 countries 2009 7.3 6 11 – –
Turkey 2010 18.7 13 27 25.6 –
Iran 2012 0.7 0 1.4 – 58.5 
France 2012–
13 
0 0 0 –
Australia 2014 – 0 0.5 – 17.2 




















































































b  he Hajj 
The Muslim pilgrimage to Makkah, the Hajj, is one of the largest
nd most ethnically diverse annual mass gatherings in the world.
uring the pilgrimage, people are in heavily over-crowded condi-
ions and live in close proximity to one another ( > 2 million pil-
rims). A large proportion of those attending are elderly or have
nderlying health conditions, with respiratory tract infections be-
ng very common (up to 80% suffer from a cough during the
ajj). 103 
There are multiple factors to consider for IMD outbreaks dur-
ng the Hajj, which include: carriage and transmission, disease, and
revention. The carriage rate among pre-Hajj pilgrims is low com-
ared with post-Hajj carriage. 104 However, the percentage of carri-
rs is generally high among household contacts following the Hajj
8.2–25.6%), as indicated in Table 2 . 104 These individuals may not
e vaccinated and are considered at risk. Since the 20 0 0 interna-
ional Hajj-related meningococcal disease outbreak, serogroup W
as been one of the most prevalent strains among pilgrims follow-
ng the Hajj, with serogroup B cases also increasing. 104 
There have been several outbreaks of IMD in Saudi Arabia over
he past three decades, with the three most prominent occurring
n 1987 (1841 cases), 20 0 0 (338 cases) and 2001 (316 cases). 105 
he main circulating serogroup in the latter two instances was W,
hich subsequently led to a global outbreak and the international
pread of the disease. 105–107 However, there have been no recorded
ases of IMD in Makkah since 2006. 105 
Based on the size of the Hajj and the potential for IMD out-
reaks, there are a range of preventative measures to limit disease
ransmission. These include vaccination, targeted/mass chemopro-
hylaxis, health awareness campaigns, and an active surveillance
ystem. 61 Vaccination is a visa requirement for all visitors enter-
ng the Kingdom of Saudi Arabia for the Hajj. Those visitors who
ail to provide a vaccination certificate at a point of entry or who
ere vaccinated less than 10 days prior to arrival in Saudi Ara-
ia are given chemoprophylaxis to eliminate carriage and are al-
owed to participate in the Hajj. 108 This specific vaccination is also
equired for domestic pilgrims, Medina and Makkah residents and
ny person in potential close contact with pilgrims (e.g., healthcare
orkers). 108 Antibiotic prophylaxis is also a possibility for those
ilgrims travelling from a country with frequent meningococcal
eningitis epidemics. 
Across various countries, the reported uptake rate for conjugate
r polysaccharide vaccines is very high among pilgrims. 61 However,
 number of potential barriers remain for vaccine uptake. arriers to vaccination 
he Hajj 
As discussed, the Hajj is a large religious mass gathering in
akkah, with a sizable at-risk population (at least 25% of pilgrims
re > 65 years old, many with underlying health conditions). 109 A
ignificant proportion of the pilgrims also have a low level of edu-
ation or health literacy. 110 , 111 As mentioned previously, meningo-
occal vaccine uptake remains generally high among Hajj pilgrims,
articularly in recent years; 60 however, there have been very low
ates reported for pneumococcal vaccination (1.2–11.3%). 112 There
s also a discrepancy between certified and self-reported vaccina-
ion, as the latter tends to be appreciably higher than rates con-
rmed through certification. 113 
Multiple barriers to vaccination uptake exist among the Hajj
opulation. One of the most common reasons is a lack of knowl-
dge about vaccines, 114 with some pilgrims being unaware that
here is a vaccine available. 115 Equally, availability is an ongoing
ssue as vaccine shortages are a possibility. 13 Cost is also cited as
 reason for not receiving a vaccine, 114 but pilgrims will receive a
accination if the cost is low or free. In France, 100% of pilgrims
ccepted a proposed diphtheria, tetanus and pertussis vaccination
hen it was offered for free upon attending their travel clinic for
andatory vaccinations. 116 
In general, a small proportion of pilgrims do not want to be
accinated owing to misconceptions regarding immunization, such
s vaccines weakening the immune system and not being safe. 117 
here has also been evidence of certain Muslim communities re-
using vaccination on religious grounds; 118 although, the Islamic
aith generally recognizes vaccination as a means to protect life. 119 
eligious grounds 
Most religions do not offer formal advice on vaccination, with
accine refusal often centering on personal religious beliefs or
afety concerns among small denominations. However, the major
eligious faiths, including Catholicism, Islam and Hinduism, gener-
lly hold no objections to vaccination as a concept. 120 
Despite the lack of resistance to vaccination, there has been 60
utbreaks of vaccine-preventable disease reported in religious set-
ings. 120 Such outbreaks often occur within small religious commu-
ities or sects across Canada and the USA. These outbreaks include,
ut are not limited to, measles, with 400 cases in British Columbia
















































































































(linked to the Netherlands Reformed Congregation); > 2499 cases
in the Dutch ‘Bible Belt’; and > 500 cases connected to Orthodox
Jewish communities in New York. 121–123 As the latter community
does not prohibit vaccination as part of their religious doctrine, the
reasons behind this outbreak remain somewhat unclear. 
In the case of the Dutch ‘Bible Belt’, a few hundred thousand
orthodox protestants, part of the Dutch Reformed Church, object to
vaccination. This initially stemmed from a fear of adverse events,
but has developed into a link with religious doctrine. 
Vaccine components are another concern for certain religious
groups. For instance, whether a vaccine is Halal is a legitimate
issue for some in the Muslim faith, with Islamic law prohibiting
medicines from ‘haram’ sources (i.e., containing ingredients with
porcine elements or relevant derivatives). 124 It is considered the
most important factor for vaccine acceptance in Muslim-majority
countries, 125 which is borne out through examples of certain vac-
cines being declared ‘haram’ by Islamic leaders. This was the case
in 2018, when the Indonesian Ulama Council in Jakarta made such
a declaration against a measles and rubella vaccine. This impacted
the success of a mass immunization campaign, launched by the
Ministry of Health, to vaccinate 67 million children aged 9 months
to 15 years. 126 The first phase of the campaign in 2017 was a suc-
cess, with Java reaching the 95% coverage target. However, since
the ruling, coverage on other islands has been lower, reaching only
68% so far. 126 
To improve vaccination uptake, it remains critically important
for governments, health officials, and religious leaders to educate
and inform the public on the benefits of vaccination. The recent
Dakar Declaration on Vaccination states that vaccination is not in
contravention of Islamic law. 127 However, the impetus should be
placed on tailor-made and targeted education in different coun-
tries, which involves local religious leaders. 
Groups at risk of invasive disease 
Occupational risks 
Various forms of employment may carry a certain risk of being
exposed to invasive bacteria; particularly among those handling
specimens in a laboratory setting. A safety cabinet should always
be used when preparing and handling specimens of meningo-
cocci. 128 , 129 In the UK, Public Health England staff working with
meningococci are offered MenACWY conjugate vaccine, with boost-
ers every 5 years, as well as two doses of 4CMenB. However,
immunization is seen as the ‘last line of defense’. Any staff
who are potentially exposed to live meningococci are prescribed
ciprofloxacin prophylaxis, even if the worker is fully vaccinated.
Such protocols may vary in other countries. 
Other occupations, which are not associated with laboratory
work, also carry a risk of meningococcal exposure and carriage
or progression to IMD. Although there is limited direct evidence,
coal miners may be at risk of exposure to N. meningitidis . A recent
study found a positive correlation between meningococcal menin-
gitis rates and male occupation rates for coal mining in England
and Wales during the national epidemic of 1931–1932. 130 
The risk of meningococcal disease may also be evident in other
heavy industries. In 2010, there was an outbreak of meningococcal
disease (serogroup C) among workers at an oil refinery in Paulinia,
Brazil. Six IMD cases occurred among workers, with another 12
cases reported in the adjacent community of Cosmopolis in Sao
Paulo state. 131 All isolates had the phenotype C:23:P1.14–6, with a
close genetic relationship. 131 Ultimately, 15,848 workers at the re-
finery were vaccinated following the outbreak, with another 18,571
people offered a MenC conjugate or MenAC polysaccharide vaccine
in the local community. 131 Welders may also be at increased risk of meningococcal dis-
ase; although, this is based on limited evidence of an increased
isk of pneumococcal disease in this population. 132 , 133 
omplement deficiencies 
A proportion of patients with IMD may have a complement
eficiency, ranging from 13% to 39%, according to numerous re-
orts. 134 , 135 
The complement system is a crucial component of the hu-
oral innate immune system. It comprises acute-phase proteins
19 plasma and at least 9 membrane proteins), with concentrations
uctuating over time. The system serves as a link to the cellular
nnate immune system and to the adaptive immune response. 136 
The system is activated through three pathways: the classical
athway (C1, C2, C4); the lectin pathway; and an alternative (ini-
ial C3 convertase and downstream). These pathways converge to-
ards a terminal pathway (C5 to C9). 137 The end product of the
erminal pathway is the formation of a stable pore within bacterial
ell membrane, leading to lysis. This system is tightly regulated to
void damage to the self. Deficiencies in the terminal pathway are
ssociated specifically with invasive Neisseria infections. 137 The in-
idence of these deficiencies varies worldwide but C9 deficiency is
requent among Japanese population (up to 1/10 0 0). 138 The bacte-
ia are also adept at evading complement-mediated killing through
olecular mimicry, as well as phase and antigenic variation. 138 
onclusions 
The risk and burden of IMD across the Asia–Pacific region is rel-
tively low, with a degree of surveillance in place. As described,
owever, monitoring practices vary and a minority of countries
o not consider IMD a notifiable disease, which leads to under-
eporting. Irrespective of these discrepancies in practice, specific
ountries across Asia and the Pacific region have now implemented
erotyping or genotypic/genomic analysis for case confirmation and
train tracking. 
Based on available data, the incidence of IMD remains low
cross the region, with outbreaks predominantly occurring among
ertain sub-populations. However, the expansion of specific clonal
omplexes, particularly cc4821 and cc11, remains a source of con-
ern as isolates have exhibited some level of non-susceptibility to
ntibiotics. The issue of antimicrobial resistance was consistently
evisited during the GMI meeting. 
In terms of IMD treatment and prevention, meningococcal vac-
ination is not included in the majority of NIPs across the region.
owever, specific vaccines do form part of national recommenda-
ions for high-risk individuals, be they travelers or those with com-
lement deficiencies or HIV. Even so, there are a number of poten-
ial barriers to vaccine uptake, including cost, availability, a lack
f knowledge or basic medical knowledge, as well as misconcep-
ions surrounding vaccination. Religious beliefs may also conflict
ith vaccination; albeit to a small degree as most major religions
o not oppose the strategy. 
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